WuXi Biologics to launch in US: Tax reform makes ‘investment thesis much stronger’ says CEO

By Flora Southey contact

- Last updated on GMT

(Image: Getty/lukbar)
(Image: Getty/lukbar)
WuXi Biologics has announced plans to build a $60m manufacturing facility – offering continuous manufacturing options – for clinical and commercial production in the US.

The Chinese contract development and manufacturing organisation (CDMO) will invest $60m (€51m) in the Worcester, Massachusetts-based site and hire approximately 150 employees.

The so-called “factory of the future” will house approximately 4,500L bioreactor capacity, with two 2,000L traditional fed-batch and one perfusion-based for continuous processing.

“Based on what we understand on the competition, this is likely the first GMP [good manufacturing practice] facility offering continuous manufacturing option,” ​CEO Chris Chen told us.

The facility – which Chen said is located within two hours of a number of WuXi Biologics partners – responds to the global demand for increased manufacturing capacity.

“We have a growing portfolio of 161 molecules to be developed from global clients as of Jan 1 2018. Based on progress of the pipeline we know when we need capacity and how much we need. We then plan it in our global manufacturing network,”​ he explained.

According to Chen, the passing of the Tax Cuts and Jobs Act of 2017 – which reduced the US corporate tax rate from 35% to a flat 21% - also makes the US an attractive option for investment.

“[The] lower tax rate definitely makes the investment thesis much stronger than last year​,” he told us.

The investment marks WuXi Biologics’ eleventh drug substance manufacturing facility globally and its third outside of China.  

In late April this year​, the firm said it planned to build a biologics manufacturing facility in Ireland. The following month​, WuXi Biologics announced plans to expand manufacturing to Singapore with the construction of a $60m facility.  

Related topics: Bio Developments, Bio-Outsourcing

Related news

Show more

Related products

show more

Seasonal Vaccine Manufacturing

Seasonal Vaccine Manufacturing

Baxter BioPharma Solutions | 10-Feb-2021 | Technical / White Paper

The production of seasonal vaccines, such as those for influenza, presents unique challenges to manufacturers due to the necessary time constraints resulting...

Consideration and Options for Prefilled Syringes

Consideration and Options for Prefilled Syringes

Baxter BioPharma Solutions | 10-Feb-2021 | Technical / White Paper

Convenience, product differentiation, and less waste are great reasons for developing a product in a prefilled syringe. Baxter’s whitepaper describes the...

Rapid Biosafety Testing Enables the Future of Manufacturing

Rapid Biosafety Testing Enables the Future of Manufacturing

Viral Safety for mAb: Prevent, Detect, Remove | 23-Nov-2020 | Technical / White Paper

This white paper explores the factors driving the evolution toward faster biosafety testing and describes rapid approaches for adventitious agent testing...

Related suppliers

Follow us


View more